Effectiveness of Dupilumab in the Treatment of Patients with Severe Uncontrolled CRSwNP: A "Real-Life" Observational Study in the First Year of Treatment

Eugenio De Corso, Stefano Settimi, Claudio Montuori, Marco Corbò, Giulio Cesare Passali, Davide Paolo Porru, Simone Lo Verde, Camilla Spanu, Daniele Penazzi, Giuseppe Alberto Di Bella, Eleonora Nucera, Matteo Bonini, Gaetano Paludetti, Jacopo Galli

Risultato della ricerca: Contributo in rivistaArticolo in rivista


The aim of this study was to evaluate the efficacy of dupilumab in the treatment of severe uncontrolled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), with or without asthma as add-on therapy with intra-nasal corticosteroids in a real-life setting over the first year of treatment. Our data demonstrated that subcutaneous 300 mg dupilumab administered at home via a pre-filled auto-injector every two weeks, based on indications set by the Italian Medicines Agency, was rapidly effective in reducing the size of polyps, decreasing symptoms of disease, improving quality of life, and recovering olfaction. Significant improvement was observed after only 15 days of treatment, and it progressively increased at 6 and 12 months. Dupilumab was also effective in reducing the local nasal eosinophilic infiltrate, in decreasing the need for surgery and/or oral corticosteroids, and in improving control of associated comorbidities such as chronic eosinophilic otitis media and bronchial asthma. After 12 months of treatment, 96.5% of patients had a moderate/excellent response. From our data, it was evident that there was a group of patients that showed a very early response within one month of therapy, another group with early response within six months from baseline, and a last group that improved later within 12 months. The results of this study support the use of dupilumab as an effective option in the current standard of care for patients affected by severe uncontrolled CRSwNP.
Lingua originaleEnglish
pagine (da-a)2684-2696
Numero di pagine13
RivistaJournal of Clinical Medicine
Stato di pubblicazionePubblicato - 2022


  • asthma
  • biologics
  • chronic rhinosinusitis with nasal polyps
  • dupilumab
  • eosinophilic otitis media
  • eosinophils
  • real life
  • treatment outcomes
  • type-2 inflammation


Entra nei temi di ricerca di 'Effectiveness of Dupilumab in the Treatment of Patients with Severe Uncontrolled CRSwNP: A "Real-Life" Observational Study in the First Year of Treatment'. Insieme formano una fingerprint unica.

Cita questo